Windlas Biotech Limited Total Assets
Windlas Biotech Limited total assets. Based on the latest financial reports, Windlas Biotech Limited (WINDLAS) holds total assets worth Rs8.14 Billion INR (≈ $88.05 Million USD) as of September 2025. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. Also see WINDLAS market cap for the company's overall valuation and market capitalisation.
Total Assets of Windlas Biotech Limited (2018–2025)
Total assets of Windlas Biotech Limited from 2018 to 2025. This chart illustrates how Windlas Biotech Limited's total assets have evolved over time, based on quarterly financial data. See Windlas Biotech Limited (WINDLAS) share price today for real-time trading data and today's change.
Windlas Biotech Limited - Asset Composition Analysis
Windlas Biotech Limited Total Assets Breakdown (March 2025)
Windlas Biotech Limited total assets breakdown as of March 2025. Windlas Biotech Limited's total assets of Rs8.14 Billion consist of 69.1% current assets and 30.9% non-current assets.
| Asset Category | Amount (INR) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | Rs0.00 | 0.1% |
| Accounts Receivable | Rs1.67 Billion | 21.9% |
| Inventory | Rs813.84 Million | 10.7% |
| Property, Plant & Equipment | Rs0.00 | 0.0% |
| Intangible Assets | Rs67.79 Million | 0.9% |
| Goodwill | Rs0.00 | 0.0% |
Asset Composition Trend (2018–2025)
This chart illustrates how Windlas Biotech Limited's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. Explore Windlas Biotech Limited current assets vs equity to assess how much short-term liquidity the company maintains relative to its equity base.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Windlas Biotech Limited's current assets represent 69.1% of total assets in 2025, an increase from 49.7% in 2018.
- Cash Position: Cash and equivalents constituted 0.1% of total assets in 2025, down from 2.5% in 2018.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 0.0% of total assets, a decrease from 15.0% in 2018.
- Asset Diversification: The largest asset category is accounts receivable at 21.9% of total assets.
Windlas Biotech Limited Competitors by Total Assets
Key competitors of Windlas Biotech Limited based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
GALDERMA GROUP AG
NYSE:GALDY
|
USA | $13.39 Billion |
|
Takeda Pharmaceutical Company Limited
F:TKDA
|
Germany | €15.41 Trillion |
|
Galderma Group N
SW:GALD
|
Switzerland | CHF12.88 Billion |
|
Enzymatica publ AB
ST:ENZY
|
Sweden | Skr149.24 Million |
|
Shijiazhuang Yiling Pharmaceutical Co Ltd
SHE:002603
|
China | CN¥13.98 Billion |
|
Hubei Jumpcan Pharmaceutical Co Ltd
SHG:600566
|
China | CN¥17.01 Billion |
|
Kangmei Pharmaceutical Co Ltd
SHG:600518
|
China | CN¥13.68 Billion |
|
Walvax BioTech
SHE:300142
|
China | CN¥10.50 Billion |
Windlas Biotech Limited - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 2.06 | 1.91 | 1.34 |
| Quick Ratio | 1.80 | 1.61 | 0.95 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | Rs2.90 Billion | Rs2.46 Billion | Rs427.40 Million |
Windlas Biotech Limited - Advanced Valuation Insights
This section examines the relationship between Windlas Biotech Limited's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 3.13 |
| Latest Market Cap to Assets Ratio | 0.03 |
| Asset Growth Rate (YoY) | 21.4% |
| Total Assets | Rs7.60 Billion |
| Market Capitalization | $199.70 Million USD |
Valuation Analysis
Below Book Valuation: The market values Windlas Biotech Limited's assets below their book value (0.03x), which may indicate investor concerns about asset quality or future growth.
Rapid Asset Growth: Windlas Biotech Limited's assets grew by 21.4% over the past year, indicating significant expansion of the company's resource base.
Annual Total Assets for Windlas Biotech Limited (2018–2025)
The table below shows the annual total assets of Windlas Biotech Limited from 2018 to 2025.
| Year | Total Assets | Change |
|---|---|---|
| 2025-03-31 | Rs7.60 Billion ≈ $82.24 Million |
+21.44% |
| 2024-03-31 | Rs6.26 Billion ≈ $67.72 Million |
+18.38% |
| 2023-03-31 | Rs5.29 Billion ≈ $57.21 Million |
+7.73% |
| 2022-03-31 | Rs4.91 Billion ≈ $53.10 Million |
+65.81% |
| 2021-03-31 | Rs2.96 Billion ≈ $32.02 Million |
-12.52% |
| 2020-03-31 | Rs3.38 Billion ≈ $36.61 Million |
+13.52% |
| 2019-03-31 | Rs2.98 Billion ≈ $32.25 Million |
+2.86% |
| 2018-03-31 | Rs2.90 Billion ≈ $31.35 Million |
-- |
About Windlas Biotech Limited
Windlas Biotech Limited, a contract development and manufacturing organization, manufactures and trades in pharmaceutical products in India. The company offers contract manufacturing; customized formulations; contract research and manufacturing services; customized formulation; and regulatory services. It also manufactures tablets, capsules, oral solids, modified-release formulations, chewable an… Read more